This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pavilion Medical Innovations And STD Med Launch Saphena Medical For Next Generation Endoscopic Vessel Harvesting Device

WEST BRIDGEWATER, Mass., Feb. 11, 2013 /PRNewswire/ -- Pavilion Medical Innovations L.L.C. of   Norwell, MA and STD Med, Inc. of Stoughton, MA are pleased to announce a joint investment to launch Saphena Medical, Inc., a new cutting edge medical device company focused on Endoscopic Vein Harvesting technologies.   Its OnePass™ platform delivers single-step, minimally-invasive harvesting of veins used for coronary artery bypass grafting. The company recently raised $3 million in Series A funding to take the OnePass™ platform through regulatory clearance.

Saphena Medical, located at the STD Med Innovation Center in West Bridgewater, MA is the fifth start-up technology company for OEM STD Med, Inc. and also the fifth for Pavilion founders, who most recently sold Vortex Medical to AngioDynamics.

Pavilion founder Michael Glennon, who will serve as the President of Saphena Medical says, "This funding and our close working relationship with the experts at STD Med will enable Saphena Medical to rapidly move our game changing platform technology through all the processes required for commercialization".   Andrea Patisteas, Senior Executive VP at STD Med said, "We are excited to join with Pavilion and share resources and expertise to successfully bring Saphena Medical's technology to market." "We both bring a lot to the table," said Steven Tallarida, President of STD Med. "Medical device incubators need to get their products to market faster and more cost effectively and that's how Mike Glennon's model works."

About Pavilion Medical Innovations (PMI) LLC:

PMI brings to life the inventions and ideas of physicians, scientists, engineers and entrepreneurs. From incubation to commercialization, PMI offers unsurpassed know-how to expedite medical technology development. We create products and companies from basic inventions, ideas and intellectual property that can improve patient outcomes and affect lives. Our deep understanding of the development process - from whiteboard to boardroom - enables us to accelerate the development of medical technology concepts in a capital-efficient manner that produces superb results for all.

About STD Med, Inc.:

STD Med, Inc. is a rapidly growing and emerging leader in the development and manufacture of medical devices and precision machined components. Established in 1953, STD Med, Inc. is a privately held company with 3 facilities in Massachusetts which are ISO 13485:2003, ISO 9001:2008, JPAL and FDA approved. Over the past several years STD Med, Inc. has incubated and invested in several new technologies including Angiolink Corporation (acquired by Medtronic), Arthrosurface Inc., Spirus Medical, Inc.(acquired by Olympus) and Cardiosolutions, Inc. and it is our intention to continue to pursue disruptive innovation in the medical device marketplace.

SOURCE Saphena Medical, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs